PHASE 2 CLINICAL EVALUATION OF PRECLINICALLY DEFINED BIOMARKERS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) TYROSINE KINASE INHIBITOR (TKI) TIVOZANIB IN RENAL CELL CARCINOMA (RCC)

被引：0
|
作者：
Hutson, T. [1 ]
Rathmell, W. K. [2 ]
Feng, B. [3 ]
Robinson, M. O. [3 ]
Gyuris, J. [3 ]
Lin, J. [3 ]
Choueiri, T. [4 ]
机构：
[1] Baylor Sammons Canc Ctr, GU Oncol Program, Dallas, TX USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, North Carolina Canc Hosp, Chapel Hill, NC 27599 USA
[3] AVEO Oncol, Clin Res, Cambridge, MA USA
[4] Dana Farber Canc Inst, Div Solid Tumor Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu326.66
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
233P
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma
    Nakagawa, M
    Emoto, A
    Hanada, T
    Nasu, N
    Nomura, Y
    BRITISH JOURNAL OF UROLOGY, 1997, 79 (05): : 681 - 687
  • [22] Efficacy of adjuvant vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (VEGFRi) in renal cell carcinoma (RCC): A systematic review and meta-analysis
    Ayer Botrel, Tobias Engel
    Clark, Otavio
    Horta Bretas, Francisco Flavio
    Sadi, Marcus V.
    Ferreira, Ubirajara
    Paladini, Luciano
    Matheus, Wagner
    Duraes, Ronilson Oliveira
    Lima Pompeu, Antonio Carlos
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [23] Vascular Endothelial Growth Factor Inhibitor Therapy and Cardiovascular and Renal Damage in Renal Cell Carcinoma
    Lai, Silvia
    Molfino, Alessio
    Seminara, Patrizia
    Longo, Flavia
    Innico, Georgie
    Coppola, Bettina
    Mastroluca, Daniela
    Galani, Alessandro
    Dimko, Mira
    Aceto, Paola
    Lai, Carlo
    CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (02) : 190 - 196
  • [24] Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).
    Almeida, Daniel Vargas
    Oliveira, Cleyton Z.
    Soares, Andrey
    Mariano, Rodrigo Coutinho
    Jardim, Denis L.
    Bastos, Diogo Assed
    Maluf, Fernando C.
    Werutsky, Gustavo
    Monteiro, Fernando Sabino M.
    Souza, Vinicius Carrera
    de Velasco, Guillermo
    Fay, Andre P.
    Sasse, Andre Deeke
    Schutz, Fabio A. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma
    Christoph W. M. Reuter
    Michael A. Morgan
    Viktor Grünwald
    Thomas R. W. Herrmann
    Martin Burchardt
    Arnold Ganser
    World Journal of Urology, 2007, 25 : 59 - 72
  • [26] Expression analysis of the vascular endothelial growth factor (VEGF) family in renal cell carcinoma: Targeting the VEGF pathway
    Lam, JS
    Leppert, JT
    Yu, H
    Seligson, DB
    Dong, J
    Horvath, S
    Pantuck, AJ
    Figlin, RA
    Belldegrun, AS
    JOURNAL OF UROLOGY, 2006, 175 (04): : 122 - 122
  • [27] Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma
    Reuter, Christoph W. M.
    Morgan, Michael A.
    Gruenwald, Viktor
    Herrmann, Thomas R. W.
    Burchardt, Martin
    Ganser, Arnold
    WORLD JOURNAL OF UROLOGY, 2007, 25 (01) : 59 - 72
  • [28] Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis.
    Bosse, Dominick
    Lin, Xun
    Simantov, Ronit
    Lalani, Aly-Khan A.
    Derweesh, Ithaar
    Chang, Steven Lee
    Choueiri, Toni K.
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [29] Hypoxia-inducible factor (HIF) 1α and 2α as predictive markers of outcome to VEGFR tyrosine kinase inhibitors (TKI) in renal cell carcinoma (RCC)
    Saez, M. I.
    Trigo Perez, Jose Manuel
    Perez-Rivas, L. G.
    Perez-Villa, L.
    Villatoro, R.
    Montesa, A.
    Cid, J. I.
    Leon, M.
    de Luque, V.
    Fernandez, C.
    Quero, C.
    Pajares, B.
    Alba, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
    Eskens, Ferry A. L. M.
    Haberkorn, Brigitte
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2012, 1 (04) : 207 - 208
12345